Award type :
Product Development Award
Product Development Award
Product type :
Vaccines
Vaccines
Award year :
2021
2021
Project start date :
06 / 22 / 2021
06 / 22 / 2021
Project end date :
08 / 31 / 2025
08 / 31 / 2025
Project duration (months) :
24
24
Development stage :
Phase 2, Phase 3
Phase 2, Phase 3
Target disease :
Schistosomiasis
Schistosomiasis
Region served :
World
World
Recipient organization / Country of funding recipient organization :
Texas Tech University Health Sciences Center (TTUHSC) / USA
Texas Tech University Health Sciences Center (TTUHSC) / USA
Collaborator(s) / Country :
Quratis / Republic of Korea, PAI Life Sciences / USA, Bharat Biotech International ltd., / India, International Vaccine Institute (IVI) / Republic of Korea
Quratis / Republic of Korea, PAI Life Sciences / USA, Bharat Biotech International ltd., / India, International Vaccine Institute (IVI) / Republic of Korea
Funding amount(KRW) :
4,000,000,000
4,000,000,000
This project aims to develop a single vial formulation for schistosomiasis vaccine by combining the SMp80 antigen and adjuvant. An advanced vaccine candidate for schistosomiasis with prophylactic, therapeutic, transmission blocking properties could have a significant impact in high endemic areas. Through this project, Texas Tech University Health Sciences Center focuses on the delivery of final dosage form of schistosomiasis vaccine with lyophilized powder in a single-dose vial for use in Phase II ~ Phase III clinical trials.